On September 6, 2022 Shuttle Pharmaceuticals Holdings, Inc. ( Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side effects, reported the closing of its initial public offering (IPO) of 1,225,888 units of common stock and warrants at a public offering price of $8.125 per unit, for aggregate proceeds of $9,960,340, before deducting underwriting discounts and estimated offering expenses (Press release, Shuttle Pharmaceuticals, SEP 6, 2022, View Source [SID1234619101]). Each unit consisted of one share of common stock and a warrant to purchase one share of common stock. Each of the warrants were exercised simultaneously with closing at an exercise price of $0.01 per share.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s common stock began trading on the Nasdaq Capital Market on August 31, 2022, under the symbol "SHPH."

Boustead Securities, LLC acted as lead underwriter and Valuable Capital Ltd. acted as co-underwriter for the offering.

The offering was made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from Boustead Securities, LLC, via email at [email protected] or by calling +1 (949) 502-4408 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus relating to the offering may be obtained via the SEC’s website at www.sec.gov.

A registration statement relating to these securities was filed with the Securities and Exchange Commission and was declared effective on August 29, 2022. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On September 6, 2022 Elephas Biosciences Corporation (Elephas), a private company, reported that it has raised $41.5 million in Series B funding (Press release, Elephas Biosciences, SEP 6, 2022, View Source [SID1234619100]). ARCH Venture Partners led the round, and were joined by new investors, Moore Strategic Ventures and Tao Capital Partners . Continuing investments were made by Northpond Ventures, Sands Capital, and WARF Ventures. Prior investments include $20 million from the Series A and $8 million from the founder and early seed investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Elephas is developing an oncology diagnostics platform to predict response to immunotherapy. The platform utilizes live fragments from a patient biopsy and treats those fragments with potential therapies and combinations. The latest advances in cancer biology combined with multi-modal imaging are used to assess how patients will respond before beginning treatment.

Elephas is launching two human clinical trials on the platform in the next quarter and plans to share initial clinical data in 2023. The company also plans to make the platform available to biopharma researchers next year. Oncology drugs remain the largest pharmaceutical therapeutic area, with immunotherapies emerging in the last decade as effective and powerful tools in the fight against cancer.

"Our mission at Elephas is to improve care for cancer patients," stated Maneesh Arora, founder and CEO of Elephas. "We are grateful for the support of these world-class venture firms who believe in what we are doing and are committed to helping us get there."

"Technology that will allow patients to receive the most effective therapy quickly, before time and resources are spent on ineffective options, will change the game for those diagnosed with cancer," ARCH Venture Partners’ Paul Berns added. "We are excited to partner with the company to bring this novel solution to patients."

XMS Capital Partners acted as financial advisor to the company.

ARCH Venture Partners’ Paul Berns will join the Elephas board of directors and ARCH’s Keith Crandell will be joining as a board observer. This follows the recent appointment by the company of Steven Galson, the former director of the Center for Drug Evaluation and Research at FDA, as independent director.

On September 6, 2022 Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, reported that Dr. Patrick Lu, PhD, founder, Chairman of the Board, Executive Director, President, and CEO of Sirnaomics, will present at the 3rd Annual Jefferies Asia Forum that will be held on September 8, 2022 (Press release, Sirnaomics, SEP 6, 2022, View Source [SID1234619099]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the presentation, there will be scheduled investor meetings at the conference. If any investors are interested in having meetings on an individual basis, please contact Sirnaomics’ Investor Relations by email: [email protected].

On September 6, 2022 Median Technologies (ALMDT) (Paris:ALMDT) reported that the Company will be participating in the 2022 ESMO (Free ESMO Whitepaper) (European Society for Medical Oncology) Congress, to be held in Paris, France, September 9-13 (venue: Paris Expo Porte de Versailles) (Press release, MEDIAN Technologies, SEP 6, 2022, View Source [SID1234619098]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will present two scientific posters. Details of the sessions include:

255P – Challenges to Assess Bone Metastases in Blinded Independent Central Review (BICR) of Breast Cancer Trials Using RECIST 1.1

Session: Breast Cancer, Metastatic
Date: Sep 10, 2022
Timeslot to meet the scientific team: 12:00 pm – 1:00 pm CEST
Place: Poster Area, Hall 4

919P – Artificial Intelligence Supporting Lung Cancer Screening: Computer Aided Diagnosis of Lung Lesions Driven by Morphological Feature Extraction

Session: New Diagnostic Tools
Date: Sep 11, 2022
Timeslot to meet the scientific team: 12:00 pm – 1:00 pm CEST
Place: Poster Area, Hall 4

During the industry exhibition, Median team will be available at booth #447, Hall 7.2 to discuss the scientific posters, present the latest developments on iBiopsy LCS CADe/CADx SaMD as well as the Company’s iCRO services for image management in oncology trials including Imaging Lab, intelligent imaging capabilities for drug development. Daily presentation sessions on Imaging Lab are planned at 3:00 pm CEST at booth.

More about the ESMO (Free ESMO Whitepaper) congress: View Source

On September Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at the hybrid H.C. Wainwright 24th Annual Global Investment Conference, which will be held September 12-14, 2022 (Press release, Puma Biotechnology, SEP 6, 2022, View Source [SID1234619097]). The virtual presentation will be available for 30 days beginning at 7:00 a.m. EDT on September 12, 2022 on the Company’s website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!